Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

VietPharma&Tech 2026

Vietnam Medical Devices Association highly appreciates Vietnam Advertisement and Fair Exhibition Joint Stock Company (VIETFAIR) organizing The international exhibition on Pharmaceutical Manufacturing Technology - VietPharmaTech 2026 / The...

Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, announced its telehealth prescribing program. This program connects eligible...

BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

UCB, a global biopharmaceutical company, announced Week 24 data for BIMZELX® (bimekizumab-bkzx) from BE BOLD, building on the study's previously reported Week 16 results, which demonstrated statistically significant superiority in ACR50 joint...

Johnson & Johnson announces that ICOTYDE® (icotrokinra), a once-daily targeted oral peptide, delivers significant improvements in psoriatic arthritis disease activity among biologic-naïve patients

Johnson & Johnson announced positive results from a Phase 3 study investigating ICOTYDE® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA).a,b ICOTYDE is the first and only targeted oral peptide that precisely blocks the...

Superpower Launches Peptide Services, Connecting Comprehensive Blood Testing With Prescription Peptide Care

Superpower, the human health company on a mission to enhance and extend human life, announces the launch of Superpower Peptides. Members can now sign up for pre-orders for prescribed peptide treatments, following clinical consults. The...

Stevanato Group and Aptar Pharma Collaborate to Accelerate Pre-Filled Syringe System Selection

Stevanato Group S.p.A. a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma to provide...

The meeting will focus on Nordic Pharma, Inc.’s patient data and study results on LACRIFILL® Canalicular Gel, a novel ocular surface therapy

Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., will be held at the annual meeting of the American Academy of Ophthalmology from 9 to 12. October in New Orleans, Louisiana, introduce the LACRIFILL ® Canalicular Gel – a novel therapy...

MedaSystems Announces Major Platform Update to Help Life Sciences Organizations Govern and Scale Expanded Access Programs

MedaSystems, a SaaS platform for managing Expanded Access, Post-Trial Access and Investigator-Initiated Study programs, announced the release of MedaSystems Version 3.3, one of the company’s most significant platform updates to date. The release...

Niagen Bioscience Puts 25 Years of NAD+ Science Behind “Don’t Get Old. Age Better.®” — a New Campaign for Its Niagen® Brand Featuring Legendary Surfer Kelly Slater

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of “Don't Get Old. Age Better.®,” a new brand campaign for its Niagen® (patented...

LEVEL Relief Protab Reduced Everyday Aches and Pain in an Independent 29-Day Study

LEVEL, a science-driven cannabinoid company, announced results from an independent 29-day real-world study of its Relief Protab, conducted in partnership with third-party research firm MoreBetter. Across 427 adults with ongoing aches and pain, the...

Stasis Introduces the First Day-and-Night Supplement System Built for Children Who Take Stimulants

Stasis, the company behind the first supplement system designed to be taken alongside stimulants, today introduced Stasis Kids, a day-and-night nutritional supplement system made for children ages 6 to 17. In 2023, 16.5 million people in the...

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

Abbott the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology. The new biowearable is designed to alert people...

European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

Acadia Pharmaceuticals Inc. announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and...

Neurolief Advances Veteran Mental Health and Migraine Care With New VA Contract for Prescription Neuromodulation

Neurolief, a neuroscience-driven medical technology company developing brain neuromodulation therapies for mental health and neurological conditions, is bringing two prescription therapies to U.S. veterans through a new Department of Veterans...

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent...

Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

Pharmacy costs are consuming a growing share of employer healthcare budgets, but high drug prices and opaque contracts do not explain the entire problem. Employers continue to face spending above expectations despite rebate guarantees, contractual...

Eligible Medicare Beneficiaries Living with Obesity Can Now Access Wegovy® Through the Medicare GLP-1 Bridge

Starting today FDA-approved Wegovy® (semaglutide) is available through the Medicare GLP-1 Bridge, a new access pathway for millions of older adults living with obesity. Obesity is a serious, common chronic disease among older Americans and Wegovy®...

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) to include children and...

Results from Incyte’s Phase 3 frontMIND Trial of Tafasitamab Combination Show Prolonged Progression-Free Survival Presented at EHA 2026

Incyte announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to...

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

ELASTEN®, Germany's 1 liquid collagen supplement and a global leader in clinically studied ingestible skincare, announced a year-long partnership with renowned board-certified dermatologist, media expert, and trusted authority in cosmetic and...

Results 1 - 20 of 104